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Background:  Isoproterenol  (ISP),  a beta-adrenergic  agonist,  suppresses  arrhythmic  storm  in patients  with
sporadic  Brugada  syndrome  (BS).  However,  the inﬂuence  of  ISP  and  the  beta-adrenergic  antagonist  pro-
pranolol  (PRO)  on  the  inducibility  and  frequency  of  ventricular  ﬁbrillation  (VF)  in  BS patients  remains
unclear.
Methods  and  results:  Twenty-seven  BS patients  with  induced  VF > 10 s  in a control  state  were  enrolled.  Elec-
trophysiological  stimulation  (EPS)  testing  was performed  during  ISP  and  after PRO in  selected  patients.
The  inducibility  and  frequency  of VF  were  compared.  Dominant  frequency  (DF) was  obtained  by Fast
Fourier  transform  from  4-s data  (phase)  and  sequentially  every  2  s up  to  phase  5.  ISP prevented  induction
of VF in  20  of  25  patients  (80%).  During  ISP,  5 patients  experienced  induction  of  VF.  ISP signiﬁcantly  inﬂu-
enced  DF  transition  compared  with  the  control  state.  DF  gradually  increased  but was  unchanged  after  theropranolol middle  phase.  PRO  had  no  effect  on incidence  of induced  VF  in  5  patients;  increased  PRO  induced  VF  in  5
(83.3%)  of  6 patients  who  tested  negative  during  ISP. After  PRO,  10 patients  experienced  induction  of  VF.
Thus,  PRO  signiﬁcantly  inﬂuenced  DF  transition.  DF after  PRO  was  higher  than  that  in the  corresponding
phase  in the  control  state.
Conclusion:  ISP  suppressed  induction  of VF and  the  increase  of  DF  with  time.  PRO  aggravated  VF  and
accelerated  DF.
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Brugada syndrome (BS) is an arrhythmogenic disease charac-
erized by an electocardiographic (ECG) pattern of the right bundle
ranch block, ST-segment elevation in the right precordial leads,
nd an increased risk of sudden cardiac death as a result of poly-
orphic ventricular tachyarrhymias or ventricular ﬁbrillation (VF)
n patients without apparent organic heart disease [1,2]. Auto-
omic function has been suggested to be related to VF in BS
3]. VF has been induced with vagal activity in patients with BS
4]. ST-segment elevation is mitigated by administration of beta-
drenergic agonists and is enhanced by parasympathetic agonists
uch as acetylcholine in experimental and clinical investigations
3–7]. The beta-adrenergic stimulator isoproterenol (ISP) has been
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raduate School of Medicine, 1-1-1 Minami-Kogushi, Ube 755-8505, Yamaguchi,
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reported to suppress arrhythmic storm in patients with sporadic
BS [7]. However, the beta-adrenergic antagonist propranolol (PRO)
has no potential to suppress VF in patients with BS [4].
Fast Fourier transform (FFT) was  used as a method of analyzing
VF cycle length [8–11] and atrial ﬁbrillation [12,13].  Spectral analy-
sis via FFT is also useful to characterize induced and spontaneous VF
cycle length [14,15].  However, information is scarce about FFT anal-
ysis of ventricular electrograms during VF, especially in patients
with BS [15].
The purpose of this study was to investigate the effects of ISP
and PRO on the inducibility and frequency of VF using FFT analysis
in patients with BS.
Methods
SubjectsThis study was  conducted between November 2003 and April
2011. Forty-three patients were enrolled. Of these, 27 males (age
50.5 ± 14.0 years; 14 symptomatic and 13 asymptomatic) who
vier Ltd. All rights reserved.
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Table  1
Clinical characteristics and the results of ventricular stimulation study.
No Age Sex Symptom FH Order in drug Control ISP BB
Induction Pacing site Induction Pacing site Induction Pacing site
1 51 M 1 0 C → ISP Positive RVA Positive RVA –
2  37 M 0 1 C → ISP Positive RVOT Positive RVOT –
3  52 M 0 0 C → ISP Positive RVA Positive RVA –
4 40 M 0 1 C → ISP Positive RVOT Negative# –
5 30  M 1 0 C → ISP Positive RVOT Negative# –
6  50 M 2 0 C → ISP Positive RVA Negative –
7  68 M 1 0 C → ISP Positive RVA Negative –
8  63 M 1 0 C → ISP Positive RVA Negative –
9  57 M 1 0 C → ISP Positive RVA Negative –
10 53 M 1 0 C → ISP Positive RVOT Negative –
11 62 M 1  0 C → ISP Positive RVOT Negative –
12  25 M 1 1 C → ISP Positive RVOT Negative –
13 26  M 0 0 C → ISP Positive RVOT Negative –
14  37 M 0 1 C → ISP Positive RVOT Negative –
15  46 M 0 0 C → ISP Positive RVOT Negative –
16  39 M 0 0 C → ISP Positive RVOT Negative –
17  55 M 2 1 C → ISP → PRO Positive RVA Negative Positive RVOT
18  28 M 2 0 C → ISP → PRO Positive RVOT Negative Positive RVOT
19 59 M 1 0 C → ISP → PRO Positive RVOT Negative Positive RVOT
20  62 M 0 0 C → ISP → PRO Positive RVOT Negative Negative
21 62  M 0 0 C → ISP → PRO Positive RVA Negative Positive RVA
22  62 M 0 0 C → ISP → PRO Positive RVOT Negative Positive RVA
23  77 M 1 0 C → BB → ISP Positive RVA Positive RVOT Positive RVA
24  71 M 0 1 C → BB → ISP Positive RVA Positive RVA Positive RVA
25  54 M 0 0 C → BB → ISP Positive RVA Negative Positive RVOT
26 48 M 1 0 C → BB Positive RVA – Positive RVOT
27  50 M 0 0 C → BB Positive RVOT – Positive RVOT
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1,  male; FH, family history of sudden cardiac death; ISP, isoproterenolol; PRO, a
entricular outﬂow tract, –, not done; #, non-sustained polymorphic ventricular ta
ulﬁlled the following study criteria were selected: (1) diagnosis
f BS; (2) VF > 10 s induced from 2 right ventricular sites [right ven-
ricular apex (RVA) and/or right ventricular outﬂow tract (RVOT)]
n the control state; (3) electrophysiological stimulation (EPS) also
erformed during administration of ISP and/or after intravenous
njection of PRO. In this study, symptomatic was deﬁned as patients
ith a history of documented ventricular tachycardia (VT), VF, or a
istory of syncope, and asymptomatic was deﬁned as patients with-
ut episodes of documented lethal ventricular arrhythmia and/or
yncope.
In addition, patients had undergone ECG, Na+ channel blocker
hallenge testing, coronary angiography, and cardiac echocardiog-
aphy during their hospitalization (Table 1).
Diagnosis of BS was based on criteria from a previous report
16] as follows: type 1 ECG shown spontaneously or in response
o Na+ channel blocker challenge testing in the standard right
recordial leads (leads V1–3) or one intercostal space above the
tandard right precordial leads, and absence of other factors such
s ischemia, electrolyte disturbance, or hypothermia that may
ause ST-segment abnormality. All patients underwent echocar-
iography with careful attention to RV enlargement and/or wall
otion abnormalities to exclude arrhythmogenic RV cardiomyopa-
hy. Implantable cardioverter–deﬁbrillators were implanted in 3
atients in the asymptomatic group and 9 patients in the symp-
omatic group.
Patients provided written informed consent. This study was
pproved by the Institutional Clinical Research and Ethics Com-
ittee of Yamaguchi Graduate School of Medicine.
a+ channel blocker challenge testingNa+ channel blocker challenge testing was performed using
ilsicainide, as previously reported [16]. The so-called “pure Na+
hannel blocker” pilsicainide was administered intravenously at
 mg/kg for 10 min  with continuous ECG and non-invasive bloodstration of propranolol (i.v.); C, control; RVA, right ventricular apex; RVOT, right
dia was induced.
pressure monitoring. During drug administration, we started mon-
itoring not only the standard right precordial leads V1–3, but also
those recorded from 1 intercostal space higher than the right pre-
cordial leads using the V4–6 electrodes. Drug administration was
immediately stopped when ST elevation (>0.5 mV), extensive QRS
prolongation, unfavorable symptoms, and/or frequent ventricular
arrhythmias were observed. The test was considered positive if
the coved-type ECG pattern (type 1 ECG) appeared in more than
one right precordial lead. Further, the additional ST elevation more
than 1 mm was  positive when the patient had already type 1 ECG
immediately before Na+ channel blocker challenge testing.
Electrophysiological testing
EPS was performed as reported previously [17,18]. Patients
underwent testing in the fasting state. All previous anti-arrhythmic
agents had been discontinued for at least ﬁve half-lives. An intra-
venous propofol infusion was  used to achieve general anesthesia.
Recordings
A standard 6F decapolar catheter with 2-mm-wide electrodes
and 2-mm interelectrode spacing were positioned in the high lat-
eral right atrium, His bundle region, coronary sinus, RVA, and RVOT.
The 12-lead surface ECG leads were recorded through a 0.5–100-Hz
ﬁlter. ECG was recorded simultaneously with intracardiac elec-
trograms (ICEs). Bipolar endocardial electrograms were recorded
through a 30–150 Hz ﬁlter with a sampling interval of 1 kHz using a
computed electric recorder (CardioLAB v51D, GE Medical Systems,
Waukesha, WI,  USA).
Stimulation protocol
Programmed electrical stimulation was  delivered at twice the
diastolic threshold at a pulse width of 2 ms  (Fukuda-denshi, Tokyo,
Japan). Programmed stimulation at basic cycle lengths of 600 and
400 ms  at the RVA pacing site started with up to 2 extrastimuli and
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 minimum coupling interval of S2S3 180 ms.  The same method
as used at the RVOT pacing site. Then, programmed stimulation
ith 3 extrastimuli and minimum coupling intervals of S2S3 and
3S4 200 ms  and rapid pacing down to a cycle length of 240 ms  or
:1 ventricular response were performed at the RVA site. Finally,
he same method was used at the RVOT pacing site. When VF was
nduced during pacing, cardioversion therapy was initiated after
bservation for several seconds to conﬁrm lack of spontaneous
ermination. Direct current (DC) shock was then delivered. Stimula-
ion resumed 5 min  after successful cardioversion in all induced VF.
n only one VF episode, cardioversion was not performed because
F terminated spontaneously at 15.8 s immediately before the
elivery of DC.
SP and PRO administration
After examination of the control state, ISP was  administered as
 bolus injection intravenously at a dose of 1–2 g, followed by
ontinuous ISP infusion at a dose of 0.15–0.30 g/min until base-
ine heart rate increased 20 bpm, at which point EPS was  begun.
ixteen patients received ISP alone (case no. 1–16 in Table 1). In 6
atients, PRO (total dose: 0.1 mg/kg) was injected intravenously at
 mg/min after EPS under ISP, and EPS was restarted (case no. 17–22
n Table 1). In 3 patients, EPS during ISP was performed after EPS of
RO (case no. 23–25 in Table 1). In 2 patients, EPS was  performed
n the control state and after the administration of PRO (case no.
6–27 in Table 1).
We measured heart rate just before EPS in the control state and
SP, and then calculated the increased rate of the heart rate (%), (the
ifference of the heart rate before EPS between control state and
SP/the heart rate in control) × 100, to assess the effect of ISP.
In the present study, VF was deﬁned as a fast irregular ven-
ricular rhythm with a continuously changing morphology and a
ycle length <200 ms  [19] lasting >10 s. A fast irregular ventricu-
ar rhythm with a continuously changing morphology and a cycle
ength >200 ms  for >10 s was deﬁned as non-sustained polymor-
hic VT, but not induced VF. VF duration was calculated from the
ast stimulation to the last beat of VF.
ignal processing and FFT analysis
The data were analyzed using previously reported methods
13]. In brief, VF episodes were selected using CardioLAB, then
ransferred to a hard disk. Next, binary data from the ventricular
lectrogram were retrieved from the hard disk of the Cardio-
AB system using a USB and made compatible with multipurpose
hysio-informatic analysis software (BIMUTAS II for Windows, KIS-
EI COMTEC, Ltd., Tokyo, Japan) on a personal computer. Finally,
 phases of 4-s data were selected as an epoch (Fig. 1A). Surface
CG (leads I, aVF, V1, and V5) and rectiﬁed bipolar electrograms
RVOTdistal, RVOTproximal, RVAdistal, and RVAproximal) were analyzed
sing 4096-point FFT (spectral resolution: 0.24 Hz) with a Ham-
ing window [13] and the BIMUTAS II. Each of the four surface
CGs and four ICEs in each epoch was padded to 4096 points with
eros. Further, data in the last phase >2.0 s with 0-padding was
ormed to 4096 points for FFT analysis in 4 patients.
The power spectrum of electrograms at each recording site was
btained, then the dominant frequency (DF) [11–13],  deﬁned as
he frequency of the peak with the largest amplitude, was  obtained
rom each epoch in each phase. We  also assessed DF from surface
CGs to compare with the DF from bipolar electrograms.
Average DF from surface ECGs and ICEs was calculated to allow
uantitative comparison. These values were used as the DF of ECG
DFECG) and the DF of ICE (DFICE) in each phase (Fig. 1B).
The effective refractory period (ERP) was deﬁned as the maxi-
um  coupling interval during a single program stimulation with a
ailed ventricular reaction.iology 60 (2012) 47–54 49
Statistical analysis
Data are presented as mean ± SD. A simple regression test was
used to determine the relationships among the data. One-factor
ANOVA was used for the change of phase analysis. Repeated-
measure ANOVA was used to analyze differences in the change of
phase between the asymptomatic and symptomatic groups. The
chi-square test for independence was  used for comparisons of
prevalence. Student’s t-test (unpaired or paired) was also used as
appropriate. These analyses were performed using StatView 5.0 for
Windows (SAS Institute Inc., Cary, NC, USA).
Results
ERPs and inducibility in controls, ISP, and PRO
ISP signiﬁcantly shortened the ERP in both the RVA and RVOT
at basic cycle lengths of 600 and 400 ms  (Table 2). However, there
was no signiﬁcant difference in ERP in either the RVA or RVOT at
cycle lengths of 600 and 400 ms  for PRO (Table 2).
The mean VF duration was 14.6 ± 2.0 s in the control study
(n = 27), 14.5 ± 1.5 s in the ISP study (n = 5), and 14.5 ± 2.1 s in the
PRO study (n = 10). ISP decreased the incidence of induced VF from
22 patients to 3 patients (13.6%). Thus, ISP prevented VF induc-
tion in 19 patients (86.4%), including 2 patients with non-sustained
polymorphic VT (Fig. 2). ISP also suppressed VF in 1 (33.3%) of 3
patients who  tested positive after PRO (Fig. 3 and Table 1).
ISP signiﬁcantly (p < 0.0001) increased the heat rate just before
EPS from control state (64.9 ± 9.5 beats/min) to ISP (86.1 ± 14.2
beats/min). There was  no signiﬁcant difference of heart rate
just before EPS in the control state between the negative VF
group (65.6 ± 9.7 beats/min) and the positive VF group (62.4 ± 9.7
beats/min). Neither, there was  no signiﬁcant difference (p = 0.083)
of the heart rate just before EPS in ISP between the neg-
ative VF group (88.7 ± 13.6 beats/min) and the positive VF
group (75.6 ± 12.6 beats/min). There was  a signiﬁcant difference
(p = 0.009) of the increase rate of the heart rate between the nega-
tive VF group during EPS in ISP (20.9% ± 4.6%) and the positive VF
group during EPS in ISP (37.3% ± 24.0%).
On the other hand, PRO did not change the incidence of induced
VF in the 5 patients. In some patients (Fig. 4), ventricular ﬁbrillation
was induced in a lower stimulation mode, and surface ECG during
VF was disorganized compared with that in the control state. PRO
also induced VF in 5 (83.3%) of 6 patients who tested negative after
ISP (Fig. 3 and Table 1).
DF transition of VF with phase in the control state
In the control state (n = 27), the duration of induced
VF was 14.6 ± 2.0 s. DFECG signiﬁcantly increased with phase
(p < 0.0001, one-factor ANOVA; 5.61 ± 0.40 Hz, 5.74 ± 0.53 Hz,
6.07 ± 0.36 Hz, 6.13 ± 0.52 Hz, and 6.14 ± 0.50 Hz in phases 1, 2,
3, 4, and 5, respectively; Fig. 5, left panel). DFICE also sig-
niﬁcantly increased with phase (p = 0.0006, one-factor ANOVA;
5.72 ± 0.38 Hz, 5.88 ± 0.43 Hz, 6.05 ± 0.37 Hz, 6.14 ± 0.48 Hz, and
6.18 ± 0.51 Hz in phases 1, 2, 3, 4, and 5, respectively; Fig. 5, right
panel).
DF transition with phase during ISP
VF was  induced in only 5 patients during ISP. In the corre-
sponding cases (n = 5), DFECG in the control state was 5.63 ± 0.32 Hz,
5.89 ± 0.30 Hz, 6.07 ± 0.36 Hz, 6.13 ± 0.33 Hz, and 6.18 ± 0.39 Hz
in phases 1, 2, 3, 4, and 5, respectively. DFECG during ISP was
5.84 ± 0.13 Hz, 6.12 ± 0.17 Hz, 6.27 ± 0.11 Hz, 6.17 ± 0.19 Hz, and
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Fig. 1. (A) Representative case of induced ventricular ﬁbrillation (VF) in the control state. Surface electrocardiogram and intracardiac electrogram in a patient with symp-
tomatic Brugada syndrome (case 5, Table 1). VF was induced by double-mode ventricular stimulation (S1/S2/S3 = 600/270/210 ms)  from the right ventricular outﬂow tract
(RVOT)  site. Phase number indicates the 4-s data segment. (B) A Fast Fourier transform (FFT) analysis as in Fig. 2A. Raw data of FFT analysis in phase 1 (left panel) and phase 5
(right  panel) are shown. The dominant frequency (DF) is indicated by the number, and the dot represents the maximum point in the power spectrum. DF of ECG (DFECG) was
calculated as the mean DF (in leads I, aVF, V, and V5). The DF of intracardiac ECG (DFICE) was  calculated as the mean DF (in RVOTd, RVOTp, RVAd, and RVAp). Both DFECG and
DFICE in phase 5 were higher than those in phase 1. The dotted line marks 6.0 Hz. DC, direct current shock delivery; RVAd, the distal pair of the right ventricular apex; RVAp,
the  proximal pair of the right ventricular apex; RVOTd, the distal pair of the right ventricular outﬂow tract; RVOTp, the proximal pair of the right ventricular outﬂow tract.
Table  2
Effective refractory periods of basic cycle lengths of 600 and 400 ms  in the control state, isoproterenol (ISP), and propranolol (PRO).
Control vs. ISP Control vs. PRO
BCL 600 ms
RVA (ms) 234 ± 15 vs. 226 ± 13, n = 16, p = 0.034 238 ± 17 vs. 236 ± 9, n = 11, p = 0.749
RVOT  (ms) 230 ± 12 vs. 219 ± 14, n = 16, p = 0.029 236 ± 13 vs. 232 ± 12, n = 11, p = 0.309
BCL  400 ms
RVA (ms) 213 ± 11 vs. 203 ± 12, n = 25, p = 0.001 213 ± 14 vs. 215 ± 13, n = 11, p = 0.391
RVOT  (ms) 220 ± 17 vs. 203 ± 16, n = 25, p = 0.002 219 ± 10 vs. 216 ± 12, n = 11, p = 0.343
Comparison of the control state with ISP or PRO was performed only in corresponding data.
BCL, basic cycle length; ISP, isoproterenol; PRO, propranolol. ISP signiﬁcantly shortened the effective refractory period in both the right ventricular apex (RVA) and the right
ventricular outﬂow tract (RVOT) at basic cycle lengths of 600 and 400 ms.
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Fig. 2. Non-sustained polymorphic ventricular tachycardia was  only induced during
isoproterenol drip infusion in case 5. RVOT, right ventricular outﬂow tract; RVAd,
the distal pair of the right ventricular apex; RVAp, the proximal pair of the right
ventricular apex; RVOTd, the distal pair of the right ventricular outﬂow tract; RVOTp,
t
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Fig. 3. Results of ventricular stimulation and pharmacological testing. VF(+): pos-
itive induction of ventricular ﬁbrillation; VF(−), negative induction of ventricular
F
s
phe proximal pair of the right ventricular outﬂow tract.
.14 ± 0.28 Hz in phases 1, 2, 3, 4, and 5, respectively. By con-
rast, DFICE in the control state was 5.63 ± 0.30 Hz, 5.75 ± 0.33 Hz,
.00 ± 0.21 Hz, 6.15 ± 0.29 Hz, and 6.15 ± 0.38 Hz in phases 1, 2,
, 4, and 5, respectively. DFICE during ISP was 5.94 ± 0.27 Hz,
.11 ± 0.18 Hz, 6.20 ± 0.13 Hz, 6.18 ± 0.27 Hz, and 6.06 ± 0.29 Hz in
hases 1, 2, 3, 4, and 5, respectively.
ISP signiﬁcantly inﬂuenced the transition of DFECG and DFICE
ompared with the control state (p = 0.0001 in DFECG, p = 0.005 in
FICE by repeated-measure ANOVA; Fig. 6, upper panel). Note that
FECG and DFICE gradually increased from phase 1 to phase 3 but
ot from phase 3 to phase 5.
ig. 4. Ventricular ﬁbrillation was induced from triple mode ventricular stimulation (S1
tate  (upper panel) and from double mode ventricular stimulation (S1/S2/S3 = 400/240/1
anel).  Ventricular ﬁbrillation was induced in a lower stimulation mode, and surface elecﬁbrillation; ISP, isoproterenol; PRO, propranolol; pts, patients; VT, ventricular tachy-
cardia.
DF transition with phase after PRO
VF was  induced in 10 patients after PRO. In the correspond-
ing cases (n = 10), DFECG in the control state was  5.70 ± 0.38 Hz,
5.75 ± 0.59 Hz, 6.15 ± 0.36 Hz, 6.17 ± 0.56 Hz, and 6.20 ± 0.46 Hz
in phases 1, 2, 3, 4, and 5, respectively. DFECG after PRO was
5.78 ± 0.45 Hz, 6.15 ± 0.40 Hz, 6.26 ± 0.47 Hz, 6.28 ± 0.43 Hz, and
6.49 ± 0.49 Hz in phases 1, 2, 3, 4, and 5, respectively. By con-
trast, DFICE in the control state was  5.72 ± 0.36 Hz, 5.81 ± 0.42 Hz,
6.11 ± 0.36 Hz, 6.20 ± 0.41 Hz, and 6.26 ± 0.49 Hz in phases 1, 2,
3, 4, and 5, respectively. DFICE after PRO was 5.93 ± 0.42 Hz,
6.20 ± 0.42 Hz, 6.29 ± 0.42 Hz, 6.36 ± 0.57 Hz, and 6.53 ± 0.55 Hz in
phases 1, 2, 3, 4, and 5, respectively.
PRO signiﬁcantly inﬂuenced the transition of DFECG and DFICE
compared with the control state (p < 0.0001 in DFECG, p < 0.0001 in
DFICE by repeated-measure ANOVA; Fig. 6, lower panel). Both DFECG
and DFICE after PRO were relatively high in each phase of the control
state.
/S2/S3/S4 = 600/230/200/200 ms)  at the right ventricular apex (RVA) in the control
80 ms) at the right ventricular outﬂow tract (RVOT) after propranolol i.v. (lower
trocardiogram was  disorganized compared with that in the control state.
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Fig. 5. Transition of dominant frequency of electrocardiogram (DFECG) and intracardiac electrogram (DFICE) in controls. DFECG and DFICE signiﬁcantly increased with phase
increase  (p < 0.0001 and p = 0.0006, respectively).
Fig. 6. Comparison of the transition of dominant frequency of electrocardiogram (DFECG) and intracardiac electrogram (DFICE) in the control state and drip infusion of ISP
(upper  panel) and PRO (lower panel). Transition of DFECG and DFICE with phase was signiﬁcantly inﬂuenced by both ISP infusion (p = 0.0001 in DFECG and p = 0.005 in DFICE)
a n DF w
c
D
t
s
I
l
p
H
g
f
gnd  PRO (p < 0.0001 in DFECG and p < 0.0001 in DFICE). ISP suppressed the increase i
ontrol  state. ISP, isoproterenolol; PRO, administration of propranolol.
iscussion
The occurrence of spontaneous VF in patients with BS is related
o increases in vagal tone [3].  Inversely, VF electrical storm is
ometimes prevented by the increase of sympathetic tone via
SP administration [7,20].  ST elevation in the right precordial
eads, the speciﬁc ECG pattern of BS, increases by parasym-
athetic agonists and decreases by sympathetic agonists [3].
owever, there is little information on the inﬂuence of adrener-
ic tone in the induction of VF by ventricular stimulation or VF
requency measurement by surface ECG and ventricular electro-
rams.ith phase increase. Inversely, PRO increased DF in each phase compared with the
DF transition obtained by FFT during VF
In the present study, surface ECG was analyzed without signal
processing because the shape of the waves is similar to that of sine
waves. On the other hand, bipolar electrograms were analyzed after
signal processing similar to the FFT analysis of atrial ﬁbrillation as
previously reported [13].
Electrical signal characteristics during VF in humans have been
related to the mode of induction [21], duration of the arrhythmia
[19], underlying heart disease [22], or drugs [10]. DF during VF has
been reported as a potential physiologic indicator of VF duration
[23].
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DFECG and corresponding DFICE showed similar values and the
hange with phase in present study. The close relationship between
FECG and DFICE during the initial phase of induced VF (<3.3 min)
as been reported [24]. Further, DF at the initial phase during
nduced VF was highly reproducible [25].
In the present study, both DFICE and DFECG signiﬁcantly
ncreased with phase. This is consistent with previous reports
10,11]. Initial phase DF was in the 8–12 Hz range in dogs and some-
hat lower in humans [11]. In the present study, DFICE of phase 1
n patients with BS was  5.72 ± 0.38 Hz, which was  higher than that
n previous studies [8,10].  This suggests that the initial phase DF of
nduced VF in patients with BS may  be higher than that in patients
ith apparent heart disease.
nﬂuence of adrenergic activity on DF transition during VF
ISP has been reported to suppress arrhythmic storm in sporadic
ases [7].  In the present study, DFs at the early phase 1 and 2 were
elatively higher than those of control state. This can be explained
y the ventricular ERP shortened by ISP. It seemed that the increase
f DF at the late phase since phase 3 (4–8 s) was suppressed by ISP.
n the other hand, PRO signiﬁcantly accelerated DF from phase 1
ompared with that in the control state.
In VF, a conduction delay occurs at the anterior wall and outﬂow
ract of the right ventricle and is possibly exacerbated by an abrupt
ise in vagal activity, inducing the random reentry that results in VF
3]. Therefore, VF suppression may  result from the improvement
f a conduction delay at the RVOT site by ISP. In another mech-
nism, beta-adrenergic stimulation induces the increased inward
alcium current and attenuates excess of the outward current,
esulting in action potential change, which suppresses phase 2
eentry [26]. Unfortunately, the detailed mechanism of VF sup-
ression is not clear. However, the results of the present study
re consistent with suppression of the electrical storm of VF by
SP [7,20] and a decrease of the J point in the right precordial lead
3].
Beta-blockers are ineffective for VF in patients with BS [3]. In the
resent study, beta-blockers have been shown to have the potential
o aggravate VF in patients with BS.
imitations of the present study
This study has several limitations. First, the sample sizes were
mall. Second, EPS during ISP after PRO may  still be inﬂuenced
y PRO because of the relatively long half-life of PRO. In fact, the
ncreased rate of the heart rate of the negative VF group during EPS
n ISP was signiﬁcantly smaller than that of the positive VF group
uring EPS in ISP. This result may  suggest the inducibility of VF dur-
ng ISP depends on the effect of ISP on the sympathetic system. In
ther words, the inducibility of VF during ISP depends on the con-
entration of ISP. But, we need further examination of this issue.
hird, 2 of the 5 patients underwent administration of PRO before
SP, and 5 of the 10 patients were subjected to ISP injection before
RO. The results of DF transition in two groups may  be inﬂuenced
y these pre-medications. Fourth, clinical and induced VF episodes
n humans may  have different spectral characteristics [9].  However,
hanges in DF from induced VF should be reﬂected by the substrate
f VF and in the electrophysiological characteristics in patients with
S.
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